

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
10 April 2008 (10.04.2008)

PCT

(10) International Publication Number
WO 2008/040934 A1

(51) International Patent Classification:

C07C 259/06 (2006.01) A61K 31/496 (2006.01)
C07C 311/19 (2006.01) A61K 31/444 (2006.01)
C07D 209/20 (2006.01) A61K 31/44 (2006.01)
C07D 213/56 (2006.01) A61K 31/4468 (2006.01)
C07D 211/26 (2006.01) A61K 31/445 (2006.01)
C07D 211/58 (2006.01) A61K 31/223 (2006.01)
C07D 241/04 (2006.01) A61P 35/00 (2006.01)
C07D 295/088 (2006.01)

Limited, 92 Milton Park, Abingdon, Oxfordshire OX14 4RY (GB). **DAY, Francesca, Ann** [GB/GB]; Chroma Therapeutics Limited, 93 Milton Park, Abingdon, Oxfordshire OX14 4RY (GB). **DONALD, Alastair, David, Graham** [GB/GB]; Chroma Therapeutics Ltd., 93 Milton Park, Abingdon, Oxfordshire OX14 4RY (GB).

(74) Agent: **WALLS, Alan, James**; PO Box 223, Tadworth, Surrey KT20 5YF (GB).

(21) International Application Number:

PCT/GB2007/003504

(22) International Filing Date:

14 September 2007 (14.09.2007)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0619753.7 6 October 2006 (06.10.2006) GB

(71) Applicant (for all designated States except US): **CHROMA THERAPEUTICS LTD.** [GB/GB]; 92 Milton Park, Abingdon, Oxfordshire OX14 4RY (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DAVIDSON, Alan, Hornsby** [GB/GB]; Chroma Therapeutics Ltd., 93 Milton Park, Abingdon, Oxfordshire OX14 4RY (GB). **MOFFAT, David, Festus, Charles** [GB/GB]; Chroma Therapeutics


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(54) Title: HDAC INHIBITORS



(57) Abstract: Compounds of formula (I) inhibit HDAC activity, wherein A, B and D independently represent =C- or =N-; W is a divalent radical -CH=CH- or CH₂CH₂-; R₁ is a carboxylic acid group (-COOH), or an ester group which is hydrolysable by one or more intracellular carboxylesterase enzymes to a carboxylic acid group; R₂ is the side chain of a natural or non-natural alpha amino acid; z is 0 or 1; and Y, L¹, and X¹ are as defined in the claims.



WO 2008/040934 A1